Cargando…
Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists
Autores principales: | Sharma, Ashish, Khanani, Arshad M., Parachuri, Nikulaa, Kumar, Nilesh, Bandello, Francesco, Kuppermann, Baruch D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887765/ https://www.ncbi.nlm.nih.gov/pubmed/36717931 http://dx.doi.org/10.1186/s40942-023-00446-z |
Ejemplares similares
-
Supplemental nutrition for retinal health: Evidence based analysis of commercial preparations in India
por: Sharma, Ashish, et al.
Publicado: (2022) -
Brolucizumab—another anti-VEGF or beyond
por: Sharma, Ashish, et al.
Publicado: (2020) -
Brolucizumab and immunogenicity
por: Sharma, Ashish, et al.
Publicado: (2020) -
Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020) -
Smartphone based ROP (S-ROP) screening—opportunities and challenges
por: patil, Jayaprakash, et al.
Publicado: (2020)